The current drug of choice for acute malaria is Artemisinin-based combination therapies (ACTs). ACTs reduce but do not eliminate gametocyte carriage, allowing some transmission to occur after treatment. Antibody responses directed at the sexual stages in the mosquito have been shown to reduce malaria transmission whereas little is known about antibody responses directed against gametocytes in the human host. We have described distinct antibody responses recognising gametocytes which are associated with reduced gametocyte carriage, but the target antigens are unknown. We are using molecular and immunological approaches, transcriptomics to identify and characterize gametocyte-specific antigens in order to illuminate on gametocyte immunity and to develop transmission blocking interventions. We work in close collaboration with Dr. Britta Urban at LSTM, Liverpool, UK, Prof. Colin Sutherland at the LSHTM, London, UK, Prof. Gordon Awandare, WACCBIP, Legon, Accra and Prof. Fred Binka at UHAS.